Financing ·
Radiopharm secures $8M advance on FY26 R&D tax incentive from Rockford Capital
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics has received an $8,000,000 advance under a funding facility secured against its anticipated FY26 Research and Development Tax Incentive (RDTI) from the Australian Taxation Office. The capital was provided by Rockford Capital at a commercial interest rate, with repayment due by October 26, 2027, or earlier without penalty. The funds will support the company's clinical trial pipeline and general working capital. Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in cancer.